Peptides›Metabolic›Cagrilintide

Cagrilintide

/ Long-acting amylin analog; AMY1/2/3 receptor agonist

TIER 2 · TranslationalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · AM833

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Long-acting amylin analog; AMY1/2/3 receptor agonistCATEGORY · Metabolic

Novo Nordisk Phase 2 data demonstrate standalone weight-loss efficacy. Primary development path is as the amylin component of CagriSema (combined with semaglutide).

§ B · Mechanism of action

Cagrilintide is a long-acting analog of amylin, a pancreatic beta-cell peptide co-secreted with insulin. Amylin agonism at AMY1/2/3 receptors (calcitonin-receptor/RAMP heterodimers) enhances satiety and slows gastric emptying through a pathway distinct from GLP-1.

§ C · Human clinical evidence

Phase 2 monotherapy data (Lau 2021, NEJM) in adults with overweight/obesity showed -10.8% weight change at 4.5 mg over 26 weeks. Primary development is as the cagrilintide component of CagriSema; standalone submission is not publicly known.

§ D · Primary literature

PubMed34197775Lau DCW et al. — Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial · Lancet · human-phase-2Once-weekly cagrilintide at 4.5 mg produced -10.8% weight change over 26 weeks vs -3.0% with liraglutide 3.0 mg comparator in adults with overweight/obesity.Limitations: Phase 2 dose-finding; standalone cagrilintide has not been submitted for approval separately from the CagriSema combination.2021

§ F · Safety signal

GI adverse events similar to amylin-class agents: nausea, decreased appetite, vomiting. Generally well-tolerated at therapeutic doses in Phase 2.

§ H · Regulatory status

Regulatory status

FDA status:: Investigational (Phase 3)
Compounding:: Not eligible for compounding (approved, not in shortage)

§ I · Notable gaps and controversies

Cagrilintide is not separately approved. The primary development path is as a component of CagriSema. Standalone research-chemical availability is not legitimate API supply.